Skip to main content
. 2016 May 20;5(5):e003432. doi: 10.1161/JAHA.116.003432

Figure 4.

Figure 4

Absolute risk differences in net clinical outcomes with the higher‐dose edoxaban regimen as compared to warfarin. Primary Net Clinical Outcome: stroke, systemic embolic events, major bleeding, or death from any cause. Secondary Net Clinical Outcome: disabling stroke, life‐threatening bleeding, or death from any cause. Tertiary Net Clinical Outcome: stroke, systemic embolic events, life‐threatening bleeding, or death from any cause. Higher‐dose edoxaban regimen compared to warfarin; primary net clinical outcome; age <65 years; HR 0.99 (0.82–1.18), 65 to 74 years; 0.87 (0.76–1.00), and ≥75 years; 0.88 (0.79–0.97); P interaction=0.48, secondary net clinical outcome age <65 years; HR 1.11 (0.89–1.37), 65 to 74 years; 0.81 (0.69–0.96), and ≥75 years; 0.86 (0.76–0.97); P interaction=0.07, tertiary net clinical outcomes; age <65 years; HR 1.1 (0.85–1.28), 65 to 74 years; 0.83 (0.71–0.97), and ≥75 years; 0.85 (0.76–0.97); P interaction=0.16. *P<0.05 for comparison vs warfarin. HDER indicates higher‐dose edoxaban regimen; HR, hazard ratio; Pt‐yr, patient years; yr, years.